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Abstract
Background: Integration of health services might be an efficient strategy for managing multiple chronic conditions
in sub-Saharan Africa, considering the scope of treatments and synergies in service delivery. Proven to promote
compliance, integration may lead to increased economies-of-scale. However, evidence on the socio-economic
consequences of integration for providers and patients is lacking.
We assessed the clinical resource use, staff time, relative service efficiency and overall societal costs associated with
integrating HIV, diabetes and hypertension services in single one-stop clinics where persons with one or more of
these conditions were managed.
Methods: 2273 participants living with HIV infection, diabetes, or hypertension or combinations of these conditions
were enrolled in 10 primary health facilities in Tanzania and Uganda and followed-up for up to 12 months. We
collected data on resources used from all participants and on out-of-pocket costs in a sub-sample of 1531
participants, while a facility-level costing study was conducted at each facility. Health worker time per participant
was assessed in a time-motion morbidity-stratified study among 228 participants. The mean health service cost per
month and out-of-pocket costs per participant visit were calculated in 2020 US$ prices. Nested bootstrapping from
these samples accounted for uncertainties. A data envelopment approach was used to benchmark the efficiency of
the integrated services. Last, we estimated the budgetary consequences of integration, based on prevalence-based
projections until 2025, for both country populations.
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Results: Their average retention after 1 year service follow-up was 1911/2273 (84.1%). Five hundred and eighty-two
of 2273 (25.6%) participants had two or all three chronic conditions and 1691/2273 (74.4%) had a single condition.
During the study, 84/2239 (3.8%) participants acquired a second or third condition. The mean service costs per
month of managing two conditions in a single participant were $39.11 (95% CI 33.99, 44.33), $32.18 (95% CI 30.35,
34.07) and $22.65 (95% CI 21.86, 23.43) for the combinations of HIV and diabetes and of HIV and hypertension,
diabetes and hypertension, respectively. These costs were 34.4% (95% CI 17.9%, 41.9%) lower as compared to
managing any two conditions separately in two different participants. The cost of managing an individual with all
three conditions was 48.8% (95% CI 42.1%, 55.3%) lower as compared to managing these conditions separately.
Out-of-pocket healthcare expenditure per participant per visit was $7.33 (95% CI 3.70, 15.86). This constituted 23.4%
(95% CI 9.9, 54.3) of the total monthly service expenditure per patient and 11.7% (95% CI 7.3, 22.1) of their
individual total household income. The integrated clinics’ mean efficiency benchmark score was 0.86 (range 0.30–
1.00) suggesting undercapacity that could serve more participants without compromising quality of care. The
estimated budgetary consequences of managing multi-morbidity in these types of integrated clinics is likely to
increase by 21.5% (range 19.2–23.4%) in the next 5 years, including substantial savings of 21.6% on the provision of
integrated care for vulnerable patients with multi-morbidities.
Conclusion: Integration of HIV services with diabetes and hypertension control reduces both health service and
household costs, substantially. It is likely an efficient and equitable way to address the increasing burden of
financially vulnerable households among Africa’s ageing populations.
Additional economic evidence is needed from longer-term larger-scale implementation studies to compare
extended integrated care packages directly simultaneously with evidence on sustained clinical outcomes.
Keywords: HIV control, Diabetes, Hypertension, Integrated care, Primary level, Economics, Efficiency, Vulnerable
populations, Multi-morbidity
Introduction
The burden of non-communicable diseases (NCDs) has
risen rapidly in Africa, and these diseases typically affect
younger working populations than seen in developed
countries [1–5]. Diabetes and hypertension alone are
probably responsible for more than 2 million deaths a
year on the continent [6]. Africa has a continuing high
burden of HIV infection. Up until now, health services
for HIV infection are organised in stand-alone clinics,
separate from the rest of the health system, with separ-
ate channels for drug and diagnostic procurement and
separate funding. The achievements of HIV programmes
are impressive, with over 60% of people living with HIV
infection in East and Southern Africa in regular care [7,
8]. In contrast, health care services for diabetes and
hypertension, which are also often organised separately,
are patchy, with only about 10–20% of people with these
conditions estimated to be in care [9–11].
We evaluated the provision of an integrated health
care service, via a ‘one-stop’ clinic, for a cohort of people
living with HIV infection, diabetes, hypertension, or any
combination of these conditions in Tanzania and
Uganda at primary and secondary level to assess the ac-
ceptability of integrated care if compliance in HIV con-
trol was not affected negatively as was feared by country
stake holders and health workers [12–15]. However,
chronic conditions may lead households into cata-
strophic expenditure and deeply into poverty [16]. There
are few data on the overall economic impact relating to
provision of diabetes and hypertension services in Africa
and to our knowledge none in relation to one-stop inte-
grated care that specifically includes patients with mul-
tiple conditions [17–20].
We aimed to (1) measure the health service attendance
and resource use, total time spend per patient and asso-
ciated treatment costs in our cohort, as well as the add-
itional out-of-pocket (OOP) costs per participant; (2)
assess the relative efficiency of integrating services for
HIV infection, diabetes and hypertension treatment; and
(3) assess the imminent budgetary consequences of man-
aging multi-morbidity in one-stop integrated clinics.
Methods
Study design and participants
The cohort study of integration of chronic care services,
known as the Management of Chronic Conditions in Af-
rica (MOCCA) study, has been described elsewhere [12].
In brief, 2416 individuals with either HIV, diabetes,
hypertension, or combinations of these conditions were
invited to join an integrated care clinic and 2273 were
enrolled from 5th August 2018 and 21st May 2019,
followed-up until the 30th of January 2020 [12–14]. The
clinic delivered a single model of care, to patients re-
gardless of condition. All patients were seen by the same
clinical staff and shared a single reception, waiting areas
and pharmacy, and systems for tracking and follow-up
of patients, recording of clinical notes, counselling,
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appointments, patient cards and registrations. Where
not available for patients with diabetes and hypertension,
these were set up from new and aligned with those avail-
able for people living with HIV. At the onset, missing
equipment and materials were supplemented. A re-
fresher training for 1 day was carried out, also at study
onset. Next, once-a-month continuous medication ses-
sions were held on chronic conditions with health facil-
ity staff as part of their regular schedule. These aimed to
ensure standardised clinical management in all three
conditions. A small buffer supply of drugs was available
to facilities in the event of there being interruptions to
drug supplies.
We compared the total costs per patient with multi-
morbidities to the sum of treating the same conditions
separately.
Patient selection
People were asked to become a participant in the cohort
study on voluntary basis, as we assessed if integrated
care were to be of ‘no harm’. The number of patients
with diabetes or with multiple conditions was limited;
hence, all persons presenting with diabetes or with two
or three of target conditions were invited consecutively
to join. The numbers of people in care with HIV infec-
tion or with hypertension was large and so we sampled
systematically, usually every 20th patient. In two small
clinics, we enrolled patients known to study staff and in-
vited them to the study. We excluded patients that were
severely ill and needed referral to secondary care levels
and patients that would not continue to live in the area.
Socio-economic study
The embedded economic sub-study adopted both health
service and patient perspectives, that is, a broad societal
perspective. A costing study of delivering services for
HIV, diabetes and hypertension was conducted in each
participating facility. Individual resource use was re-
corded in all participants in the overall clinical question-
naire. We collected detailed patient cost information on
the volume of resources in 1531 patients and their
households, shown in Fig. 1, on the second row. This
figure shows that in Tanzania 1041 patients were in-
cluded and in Uganda 1375. The lowest number of par-
ticipants (below 50) was in the group of participants
with both HIV and diabetes and the group with the
three target conditions. All other groups had more than
Fig. 1 Number of patients enrolled in each sub-study by diagnosis status
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200 participants with the HIV as the largest with 832
participants.
We recorded the diagnostic tests performed and the
drugs prescribed, individually. Unit costs for both indi-
vidual drugs and diagnostic tests were available at the fa-
cility level, based on suppliers’ invoices, and where they
were not available, local market prices were adopted.
Unit costs and specific diagnostic tests are shown in Ta-
bles A1 and A2, respectively, in the Additional file 1.
The direct and indirect costs were prospectively mea-
sured in the sub-sample of 1531 participants, recruited
consecutively. Also, a sub-sample of 228 participants
was enrolled randomly in a comorbidity-stratified time-
motion study to assess health worker time spent per par-
ticipant per visit (Fig. 1).
Collection of data on integrated programme overheads
A standardised costing tool [21] was administered to es-
timate facility level costs in each of the 10 facilities, both
in Uganda and Tanzania. It collected information on
numbers and level of facility health staff to estimate sal-
ary and related costs of all staff involved in integrated
service delivery. This was supplemented with informa-
tion on numbers of other staff involved in caring for the
participant, office supplies, travel expenses, utility bills,
medication, medical consumables and supplies, number
of laboratory testing, medical equipment, furniture, vehi-
cles and rental space used for client care. Rental costs
were based on the total area of the space utilised and the
average cost per square metre in each setting. Routine
information on total patient numbers at each facility
every month was collected to facilitate the attribution of
the integrated care service. The supply of drugs and
diagnostic tests was variable. Some of the facilities had
insufficient drug supply, inadequate functional labora-
tory equipment to conduct tests and some lacked the
equipment and or reagents to conduct some laboratory
tests (Table A3 in the Additional file 1). We therefore
calculated the health service cost per patient at each fa-
cility based on the observed use of resources and as-
sumed a full month’s supply of drugs and diagnostics
per each supply round.
Collection of data on participant-related out-of-pocket
costs
We administered a patient cost questionnaire to a sub-
sample of participants, sequentially (Fig. 1). Information
collected included participant income, total household
income, demographic characteristics, medical and non-
medical costs prior to attending to the health care facil-
ity and on the day of attendance, loss of earnings due to
participants attending a health care facility and details
on health care financing such as if the patients had to
borrow money or sell valuables to be able to attend the
healthcare facility. The participant’s reported monthly
income was used to calculate the value of hours lost. In
addition, we collected information on the participants’
travel time to the health facility, transport costs, costs of
meals and other out-of-pocket payments such as pay-
ments for health services and medications.
Time-motion study involving health workers and
participants
In our time-motion study, we recorded the time each
type of health facility staff spent providing care and the
time that participants spent waiting for each component
of health care. The total time spent at the facility by par-
ticipants was added to their travelling time to estimate
productivity losses related to their visit (see annex for
further details).
Statistical analysis
In an ingredient approach to collect resource use data
[22], following consolidated health economic evaluation
reporting standards (CHEERS) guidelines [23], we calcu-
lated total health service cost and out-of-pocket cost per
participant by comorbidity category. We assigned costs
related to drugs, diagnostics, programme costs (such as
staff salaries, administration, furniture and equipment),
transport and other out-of-pocket expenses, including
total loss of productivity due to time spent visiting the
facility. We used non-parametric bootstrapping [24] to
assess the uncertainties which were reported as 95%
confidence intervals (95% CI). All costs were calculated
in 2020 US$ prices. The estimated participant and
programme overhead costs for facility-level management
of diabetes and hypertension treatment were suboptimal
due to shortages of medications and staff. We calculated
the actual real-life cost and re-assigned the overheads
and personnel costs calculated for the people living with
HIV infection to those living with diabetes and hyper-
tension. The number of drug and diagnostic tests was
based on the actual reported resources used by the
participants.
We present here aggregate and country-based uncer-
tainty distributions of clinical resource use within each
subgroup group and across groups. These are deter-
mined by the health guidelines used in the training and
reinforced by repeat and continuous education sessions.
These estimates document the complete range of ser-
vices cost per individual and allows for a comparison of
distributions between the various types of patients, in
the diverse settings.
To assess and to benchmark the efficiency of the inte-
grated clinics, we applied an input-output data envelop-
ment analysis (DEA) [25–27] to measure the relative
efficiency of HIV clinics, NCD clinics and outpatient
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departments that manage HIV, diabetes and hyperten-
sion in Uganda and Tanzania.
The efficiency of a facility is defined as the ratio of the
weighted sum of outputs (total virtual output) to the
weighted sum of inputs (total virtual input), with the
weights being obtained in favour of each evaluated facil-
ity to measure the optimisation of activities processes.
Each facility is using multiple inputs to produce multiple
outputs. We denote a vector of inputs for so-called
decision-making unit (DMUs) as well as a vector of out-
puts is outputs. The model [27] is formulated and solved
for each hospital to obtain its efficiency score, once rela-
tive weights associated with the inputs and the outputs
are identified and valued, respectively. These weights are
calculated in a manner that they provide the highest
possible efficiency score for each facility under evalu-
ation [27].
We standardised key outputs given key resource inputs
of the facilities. In the computation, we re-scaled the in-
cluded output metrics between 0 and 1. A score of 1
equals the maximum outputs score observed among the
individual clinics, given the input levels. We included
the number of participants attended and diagnostic tests,
and medicines provided were used as the output bench-
marks. The number of key clinical staff was used as in-
put variables, categorised into three groups: clinicians,
nurses and other health workers which included labora-
tory technicians and pharmacists. We excluded the use
of health services or patient costs data, as these differ be-
tween the two counties. The outputs were specified as
(1) the staff workload defined as the number of full-time
staff divided by the number of daily participant visits, (2)
laboratory tests per participant defined as the number of
daily laboratory tests divided by the number of daily par-
ticipant visits and (3) drug availability defined by the
proportion of patients who receive drugs at no costs
from the facilities before stock-outs occur.
We used the empirical integration cost estimates in a
future forecasting for the two individual country settings,
based on DEA results and prevalence-based modelling
accounting for shorter survival and including the ob-
served uncertainty ranges of the total cost per patient
profile. We conservatively assumed that prevalence of
these — multiple — conditions will remain constant and
independent over time (see Additional file 1 for per
country details). The source of the country population
projections is United Nations Population Council [13].
All analyses were conducted using SAS version 9.4 (SAS
Institute, Inc., NC). The necessary assumption here is
that the estimates from the study need to be representa-
tive for similar situations, elsewhere in the two coun-
tries. Presently, this cannot be verified, and the estimates
need to be viewed at as ‘what-if’ scenarios. The uncer-
tainties in the presented changes are more driven by the
uncertainties in the demographic-epidemiological data
and included the narrow uncertainty ranges of the col-
lected cost per patient categories. Conservatively, we




Their retention in care after 1 year follow-up was 1911/
2273 (84.1%). At enrolment, 582/2273 (25.6%) partici-
pants had 2 or all 3 chronic conditions of study (referred
to hereon as multi-morbidity) while the remainder 1691/
2273 (74.4%) had a single condition. Over the course of
the study, an additional 84/2239 (3.8%) participants ac-
quired a second or third condition. Figure 1 shows the
flow diagram of participants in the economic study.
Baseline characteristics for individuals sampled to pro-
vide participant out-of-pocket expenses are shown in
Table 1. Two-thirds or more were women in each dis-
ease category. Overall, half (529/1050) were self-
employed and 19% (284/1504) reported no income.
Most participants (78%; 1159/1481) used public trans-
port to access health facilities. Strikingly, over a third of
the participants (563/1492) left a young child below the
age of 6 years at home and 10% (149/1510) asked a fam-
ily member or friend to accompany them to the health
care facility.
Table 2 shows the resources used by participants.
Overall, 1464 of 1620 (90.4%) participants with a single
condition and 619 of 653 (94.8%) with 2 or all 3 condi-
tions were on treatment for their health conditions. Of
the diagnostic tests, the most common resources were
fasting blood glucose and the plasma viral load.
Service use and costs of integrated care services for HIV
infection, diabetes and hypertension
The mean health service cost per participant per month
based on their individual resources used, assuming a full
month’s patient supply of drugs and diagnostics, and
assigning the overheads and personnel costs calculated
for the people living with HIV infection to those living
with diabetes and hypertension are shown in Table 3. In
this approach, the costs of medications and of diagnostic
tests per patient per month were higher for HIV infec-
tion than the additions of costs for diabetes or hyperten-
sion in individuals with single conditions (HIV infection
alone, diabetes alone and hypertension alone). For par-
ticipants who had multi-morbidity, their monthly drug
and diagnostic costs were simply the addition of drug
and diagnostic costs of individual conditions. Facility-
based personnel costs were similar across all conditions.
The added monthly costs of managing either hyperten-
sion or diabetes among participants living with HIV in-
fection were − $2.03 (95% CI − 4.33, 0.27) and +$ 4.89
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Table 1 The characteristics of individuals who were enrolled for patient-related costs by disease condition. Values are presented as
% (n), with the denominator given by the total count with a response for that characteristic, except for average group age.








Age Average (range) 38 (18–78) 49 (19–77) 56 (27–86) 55 (21–85)
Gender Total 1531 544 175 369 30 146 237 30
Female 71.5 (1094) 68.0 (370) 67.4 (118) 75.3 (278) 66.7 (20) 70.5 (103) 76.4 (181) 80.0 (24)
Male 28.5 (437) 32.0 (174) 32.6 (57) 24.7 (91) 33.3 (10) 29.5 (43) 23.6 (56) 20.0 (6)
Highest education level Total 1051 407 138 235 18 90 142 21
No formal education 9.4 (99) 5.9 (24) 12.3 (17) 9.8 (23) 11.1 (2) 7.8 (7) 15.5 (22) 19.0 (4)
Primary education 61.7 (648) 62.4 (254) 61.6 (85) 62.1 (146) 50.0 (9) 62.2 (56) 61.3 (87) 52.4 (11)
Secondary education 22.4 (235) 24.6 (100) 18.1 (25) 21.7 (51) 27.8 (5) 26.7 (24) 16.9 (24) 28.6 (6)
Higher education 6.6 (69) 7.1 (29) 8.0 (11) 6.4 (15) 11.1 (2) 3.3 (3) 6.3 (9) 0.0 (0)
Marital status Total 1053 407 138 236 18 90 143 21
Currently married 51.0 (537) 39.8 (162) 68.8 (95) 57.2 (135) 61.1 (11) 47.8 (43) 58.0 (83) 38.1 (8)
Separated 15.6 (164) 17.9 (73) 13.0 (18) 17.4 (41) 5.6 (1) 11.1 (10) 14.0 (20) 4.8 (1)
Widowed 14.9 (157) 9.8 (40) 8.0 (11) 18.6 (44) 11.1 (2) 26.7 (24) 17.5 (25) 52.4 (11)
Never married 13.6 (143) 25.1 (102) 9.4 (13) 4.7 (11) 16.7 (3) 4.4 (4) 7.0 (10) 0.0 (0)
Divorced 4.9 (52) 7.4 (30) 0.7 (1) 2.1 (5) 5.6 (1) 10.0 (9) 3.5 (5) 4.8 (1)
Participant’s main
occupation
Total 1050 405 138 236 18 90 142 21
Self-employed 50.4 (529) 51.1 (207) 51.4 (71) 48.3 (114) 50.0 (9) 51.1 (46) 50.0 (71) 52.4 (11)




10.2 (107) 11.1 (45) 10.1 (14) 12.7 (30) 16.7 (3) 8.9 (8) 4.9 (7) 0.0 (0)
Unemployed (able to
work)
9.5 (100) 8.6 (35) 10.9 (15) 7.2 (17) 5.6 (1) 7.8 (7) 16.2 (23) 9.5 (2)
Housewife 7.5 (79) 5.9 (24) 10.9 (15) 6.4 (15) 5.6 (1) 12.2 (11) 7.0 (10) 14.3 (3)
Unemployed (unable
to work)
5.0 (52) 2.2 (9) 2.2 (3) 9.3 (22) 0.0 (0) 7.8 (7) 5.6 (8) 14.3 (3)
Government
employee
2.9 (30) 1.2 (5) 4.3 (6) 4.7 (11) 5.6 (1) 3.3 (3) 2.8 (4) 0.0 (0)
Retired 2.3 (24) 1.5 (6) 3.6 (5) 2.5 (6) 0.0 (0) 2.2 (2) 2.1 (3) 9.5 (2)




Total 1525 544 175 363 30 146 237 30
Self 57.8 (881) 62.5 (340) 52.0 (91) 54 (196) 66.7 (20) 61.0 (89) 53.6 (127) 60.0 (18)
Spouse 19.4 (296) 19.3 (105) 26.9 (47) 18.5 (67) 20.0 (6) 13.0 (19) 20.7 (49) 10.0 (3)
Children 13.9 (212) 3.5 (19) 10.9 (19) 22.0 (80) 3.3 (1) 19.9 (29) 23.2 (55) 30.0 (9)
Brother/sister 4.1 (63) 6.8 (37) 4.6 (8) 2.8 (10) 6.7 (2) 2.1 (3) 1.3 (3) 0.0 (0)
Other 3.0 (46) 4.4 (24) 2.9 (5) 2.8 (10) 0.0 (0) 2.7 (4) 1.3 (3) 0.0 (0)
Parent 1.8 (27) 3.5 (19) 2.9 (5) 0.0 (0) 3.3 (1) 1.4 (2) 0.0 (0) 0.0 (0)
Main occupation of the
person who contributes
most in the household
Total 770 265 100 177 16 74 123 15
Self-employed 55.7 (429) 52.5 (139) 56.0 (56) 59.3 (105) 50.0 (8) 51.4 (38) 60.2 (74) 60.0 (9)
Professional 24.2 (186) 23.4 (62) 26.0 (26) 25.4 (45) 31.3 (5) 23.0 (17) 22.0 (27) 26.7 (4)
Other 10.0 (77) 13.2 (35) 7.0 (7) 7.9 (14) 0.0 (0) 14.9 (11) 6.5 (8) 13.3 (2)
Farmer 6.1 (47) 6.4 (17) 7.0 (7) 5.1 (9) 18.8 (3) 2.7 (2) 7.3 (9) 0.0 (0)
Unemployed 3.0 (23) 4.2 (11) 1.0 (1) 1.1 (2) 0.0 (0) 5.4 (4) 4.1 (5) 0.0 (0)
Housewife 1.0 (8) 0.4 (1) 3.0 (3) 1.1 (2) 0.0 (0) 2.7 (2) 0.0 (0) 0.0 (0)
Participant’s main income
is based on
Total 1504 538 171 361 30 140 235 29
Business earnings 23.7 (356) 22.1 (119) 26.9 (46) 22.7 (82) 33.3 (10) 22.9 (32) 24.3 (57) 34.5 (10)
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(95% CI − 0.36, 10.22) per participant, respectively, com-
pared to managing HIV only (Table 3). For people living
with diabetes, the additional cost of managing hyperten-
sion was $4.37 (95% CI 3.27, 5.49) per participant per
month, compared to managing diabetes only.
The mean health service costs of managing two condi-
tions in one participant were $39.11 (95% CI 33.99,
44.33), $32.18 (95% CI 30.35, 34.07) and $22.65 (95% CI
21.86, 23.43) for HIV and diabetes, HIV and hyperten-
sion, diabetes and hypertension per month, respectively.
These costs were 34.4% (95% CI 17.9%, 41.9%) lower
than managing two conditions separately in two differ-
ent participants. The cost of managing an individual
with all three conditions was $36.38 (95% CI 31.83,
41.07) per month, which was 48.8% (95% CI 42.1%,
55.3%) lower than managing 3 conditions separately in
three different participants.
Participant-related household expenditure
The overall mean participant-related cost was $7.33
(95% CI 3.70, 15.86) per visit, and this comprised con-
sultation costs, transport costs, medication costs, lost
labour and other out-of-pocket costs (Table 4). The
mean transport costs were $1.44 (95% CI 0.81, 2.18) for
a return trip to health facilities per visit in the two coun-
tries, which amounts to 4.5% (95% CI 2.1, 9.6) of the
participant’s total household income. Mean medication
costs of $2.25 (95% CI 0.00, 7.55) per participant per
month were the main drivers of patient-related costs,
mainly for participants without HIV. Overall,
participant-related costs per visit, constituted 11.7%
(95% CI 7.3, 22.1) of the monthly total household
earnings.
Participants also reported losing earnings from visiting
the facilities. This loss was nearly as much as their two-
way transport costs (Supplementary Table A4 in the
Additional file 1). The mean travelling time to reach the
facilities was 45 min in Tanzania and 30 min in Uganda,
which translates to a mean of $0.78 (95% CI 0.41, 1.31)
per return trip economic cost for loss of earnings or
productivity.
All in all, out-of-pocket healthcare expenditure per
health care visit comprised 23.4% (95% CI 9.9, 54.3) of
the total cost of integrated care (i.e., the sum of health
service and patient-related costs).
Staff- and patient-related time and time costs per visit
In our estimates, we used the observed time spent by
health care staff members to provide patient care and
calculated the involved costs per visit (Table 5). Clini-
cians spent the most time devoted to participant care,
with a mean 15.3 (95% CI 11.4, 20.3) min per partici-
pant. The staff time, hence, staff cost for providing care
to individuals with multiple conditions was similar or
was slightly higher but not significantly different from
the staff cost of caring for individuals with a single con-
dition. Clinicians took a mean time of 15.3 (95% CI 11.9,
19.6) min per participant with a single condition and
15.4 (95% CI 11.1, 20.9) min for a participant with mul-
tiple conditions, nurses a mean time of 11.1 (95% CI 6.3,
16.2) and 13.8 (95% CI 5.4, 33.7) min and laboratory
Table 1 The characteristics of individuals who were enrolled for patient-related costs by disease condition. Values are presented as
% (n), with the denominator given by the total count with a response for that characteristic, except for average group age.
(Continued)








Daily wage 27.4 (412) 32.7 (176) 26.3 (45) 19.9 (72) 16.7 (5) 25.7 (36) 31.1 (73) 17.2 (5)
Have no income 18.9 (284) 16.0 (86) 15.8 (27) 24.4 (88) 16.7 (5) 21.4 (30) 17.4 (41) 24.1 (7)
Monthly salary 16.9 (254) 19.3 (104) 15.8 (27) 18.3 (66) 16.7 (5) 15.7 (22) 11.5 (27) 10.3 (3)
Sale of farm produce 7.8 (117) 5.6 (30) 7.0 (12) 8.9 (32) 10.0 (3) 10.0 (14) 10.6 (25) 3.4 (1)
Other 5.4 (81) 4.3 (23) 8.2 (14) 5.8 (21) 6.7 (2) 4.3 (6) 5.1 (12) 10.3 (3)
Mode of transport used
today
Total 1481 526 169 358 29 137 234 28
Public transport 78.3 (1159) 83.5 (439) 75.7 (128) 66.8 (239) 93.1 (27) 88.3 (121) 76.1 (178) 96.4 (27)
Walking 19.5 (289) 14.8 (78) 21.3 (36) 30.2 (108) 6.9 (2) 10.9 (15) 21.4 (50) 0.0 (0)
Personal car 1.9 (28) 1.3 (7) 3.0 (5) 2.2 (8) 0.0 (0) 0.7 (1) 2.6 (6) 3.6 (1)
Other 0.3 (5) 0.4 (2) 0.0 (0) 0.8 (3) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Number that left young
children (aged less than
about 6 years) at home
Total 1492 533 169 360 30 138 233 29
Yes 37.7 (563) 34.5 (184) 40.8 (69) 38.9 (140) 33.3 (10) 34.1 (47) 43.8 (102) 37.9 (11)
No 62.3 (929) 65.5 (349) 59.2 (100) 61.1 (220) 66.7 (20) 65.9 (91) 56.2 (131) 62.1 (18)
Number who had to ask
someone to accompany
them
Total 1510 537 174 363 30 143 233 30
Yes 9.9 (149) 7.8 (42) 12.6 (22) 11.8 (43) 6.7 (2) 7.7 (11) 11.6 (27) 6.7 (2)
No 90.1 (1361) 92.2 (495) 87.4 (152) 88.2 (320) 93.3 (28) 92.3 (132) 88.4 (206) 93.3 (28)
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technicians 9.2 (95% CI 4.3, 17.3) and 11.5 (95% CI 7.0,
22.0) min, respectively.
The mean total time participants took at the facility
(i.e., from when they registered their arrival at the health
facility, until they left the facility care) was 145.8 (95%
CI 86.0, 184.7) min per patient. We observed that this
time estimate was not significantly different for a visit
among participants with a single condition (mean time
of 150.3 (95% CI 126.3, 176.6) min) and multiple condi-
tions (mean time of 142.4 (95% CI 74.6, 189.8) min).
This observed time translates to a mean loss of partici-
pant productivity of $1.42 (95% CI 0.85, 2.42) per par-
ticipant per visit based on the estimated participant’s
earnings per month (Table 4)
Overall, the lowest percentage reduction in monthly
income occurred among people with HIV only and those
with only hypertension, i.e., 9.3% (8.3, 10.5) and, respect-
ively 9.2% (7.5, 11.1). This was higher among people
with combinations of conditions, HIV and diabetes, HIV
and hypertension, and hypertension and diabetes. This
Table 2 Resource use description showing the proportion of individuals who were on medication and the number of laboratory
tests performed during the study follow-up
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(12.5%)





Viral load test 597
(75.1)
0 (0.0) 0 (0.0) 34 (77.3) 160 (65.3) 0 (0.0) 31 (64.6)
CD4 count test 87
(10.9)
0 (0.0) 0 (0.0) 2 (4.5) 23 (9.4) 0 (0.0) 3 (6.3)
HbA1c test 7 (0.9) 171 (59.4) 4 (0.7) 22 (50.0) 2 (0.8) 130 (41.1) 22 (45.8)
Fasting blood
sugar test
33 (4.2) 273 (94.8) 45 (8.4) 34 (77.3) 10 (4.1) 300 (94.9) 42 (87.5)
Random blood
sugar test
48 (6.0) 104 (36.1) 42 (7.8) 13 (29.5) 12 (4.9) 130 (41.1) 16 (33.3)
Haemoglobin test 41 (5.2) 7 (2.4) 5 (0.9) 2 (4.5) 12 (4.9) 2 (0.6) 3 (6.3)
Cholesterol test 6 (0.8) 34 (11.8) 28 (5.2) 2 (4.5) 6 (2.4) 26 (8.2) 1 (2.1)
Creatinine test 14 (1.8) 25 (8.7) 19 (3.5) 3 (6.8) 4 (1.6) 22 (7.0) 1 (2.1)
Urine test 7 (0.9) 11 (3.8) 15 (2.8) 2 (4.5) 5 (2.0) 17 (5.4) 2 (4.2)
Renal and liver
function test
4 (0.5) 16 (5.6) 20 (3.7) 3 (6.7) 13 (6.1) 41 (13.0) 3 (6.3)
Other testsb 73 (9.2) 63 (21.9) 62 (11.5) 14 (31.1) 43 (20.2) 62 (19.7) 6 (12.5)
aNumber of patients with at least a test performed during the follow-up period
bOther tests include tests such as pregnancy test, syphilis, malaria test, etc.
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was respectively 17.8% (9.3, 27.5), 11.7% (8.9, 14.8) and
12.2% (10.0, 14.6). Hence, the latter are the groups that
benefit most from one-stop clinics and become less fi-
nancially challenged.
Benchmark efficiency of service provision among
integrated health facilities
To assess the efficiency changes of service delivery
through the integration of services, we used the staff
numbers, the number of diagnostic tests and drug avail-
ability collected at each facility (grouped as HIV clinics,
NCD clinics and outpatient departments) as key quality
indicators for each facility performance. We show that
there was a varying level of efficiency in the service de-
livery among some sites (Table 6), as the mean efficiency
score of a scale from 0.0 to 1.0 was 0.86 (range for all 10
facilities, 0.30–1.00). This suggests that some facilities
had room to add additional participants without the
need to increase the key staff numbers and without com-
promising their current standard or quality of care. So
some HIV clinics and outpatient departments had cap-
acity to accommodate extra participants without extra
staff costs, whereas none of NCD clinics had such extra
capacity (Table 6). We included the overcapacity esti-
mates based on the DEA to adjust the prevalence-based
budget projections downwards.
Discussion
This detailed socio-economic study shows that inte-
grated one-stop management of chronic conditions —
specifically HIV infection, diabetes and hypertension —
could reduce costs per participant between 34 to almost
50%, compared to managing each condition separately
and hence is a highly cost-saving approach in African
settings. The savings are mostly among people present-
ing with multiple conditions, who are financially most
affected. Integration lowered the mean health service
cost per visit through a one-time use of both personnel
and capital resources. Participants with multiple condi-
tions made one trip every 1 to 3 months to a health fa-
cility under the integrated care model. This is more
convenient and less costly than two or three visits as is
the case across sub-Saharan Africa now, if participants
are treated in vertical stand-alone clinicals for each
Table 3 The monthly health service cost per patient of managing individuals with one, two and three conditions in an integrated
one-stop clinic in Tanzania and Uganda. The mean costs and 95% confidence intervals reported are in 2020 US$
























































































$0.51 (0.46, 0.56) $0.38 (0.27, 0.50)










$1.37 (1.32, 1.42) $1.34 (1.16, 1.51)
aThe mean cost for antiretroviral therapy was $16.92 (95% CI 13.22, 20.84) and that of diabetes drugs was $1.62 (95% CI 0.96, 2.39)
bThe mean cost for antiretroviral therapy was $11.88 (95% CI 10.81, 12.99) and that of hypertension drugs was $2.24 (95% CI 1.91, 2.59)
cThe mean cost of diabetes medication was $1.75 (95% CI 1.44, 2.09) and that of hypertension medication was $3.24 (95% CI 2.95, 3.54)
dThe mean cost for antiretroviral therapy was $13.26 (95% CI 10.62, 16.15), hypertension drugs was $2.53 (95% CI 1.78, 3.35) and that of diabetes drugs was $1.19
(95% CI 0.64, 1.94)
1The cost of managing an individual with HIV and diabetes was − $13.39 (95% CI − 18.69, − 8.02) cheaper than managing two individuals with single conditions
of HIV and diabetes, i.e., cost reductions of 25.5% (95% CI 15.4%, 35.5%)
2The cost of managing an individual with HIV and hypertension was − $20.63 (95% CI − 23.00, − 18.31) cheaper than managing two individuals with single
conditions of HIV and hypertension, i.e., cost reductions of 39.1% (95% CI 35.1%, 42.9%)
3The cost of managing an individual with diabetes and hypertension was − $14.24 (95% CI − 15.42, − 13.05) cheaper than managing two individuals with single
conditions of diabetes and hypertension, i.e., cost reduction of 38.6% (95% CI 36.0%, 41.1%)
4The cost of managing an individual with three conditions HIV, diabetes and hypertension is − $34.72 (95% CI − 39.53, − 29.75) cheaper than the cost of
managing three individuals with single conditions of HIV, diabetes and hypertension, i.e., cost reductions of 48.8% (95% CI 42.1%, 55.3%). The overall cost of
managing individuals with multi-morbidity (2 or 3 conditions) is − $20.74 (95% CI − 37.94, − 9.83) cheaper than the cost of two or more individuals with single
conditions, i.e., cost reductions of 38.0% (95% CI 18.8%, 53.1%)
#The average additional cost per month of managing: (i) diabetes in an HIV-infected individual is $4.89 (95% CI − 0.36, 10.22), (ii) hypertension in HIV-infected
individual is − $2.03 (95% CI − 4.33, 0.27) and (iii) hypertension in diabetic individuals is $4.37 (95% CI 3.27, 5.49)
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condition. This results in huge out-of-pocket savings for
them and reduced duplication of clinical management
activities at the health service.
At the health service, the added cost of managing multi-
morbidity is essentially determined by the additional costs
of drugs and diagnostics for the second or third chronic
condition. Savings are realised through reductions in
health worker time and in patients’ time, per participant.
The time taken by health care workers, including doctors
and nurses, appeared to be similar whether they were
managing one condition or all three. This is not uncom-
mon in clinical practice. It might be possible that clinical
staff, working under resource constraints, allocate a fixed
amount of time per participant and so did not need to give
more time or attention to the multiple conditions in the
absence of specific complications. Our clinical findings on
a one-year follow-up [12] suggest that people with multi-
morbidity had better outcomes in terms of HIV viral sup-
pression, glycaemia and blood pressure control than
people with single diseases. It is more likely, that key ele-
ments of the management of chronic conditions — clin-
ical monitoring for disease progression and promoting
drug adherence — are similar for these chronic diseases
and one clinical consultation more effectively covers all of
these conditions, allowing consultation time to be saved,
more patients to be served, and better quality care to be
delivered as indicated by the better clinical outcomes [12].
A major challenge in the management of diabetes and
hypertension in Africa has been the limited and erratic
supply of drugs and diagnostics [28]. Our study shows
Table 4 Income and health cost for participants with single, two and three conditions attending an integrated one-stop clinic in
Uganda and Tanzania. The mean costs and 95% confidence intervals reported are in 2020 US$
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2.5% (2.0, 3.2) 6.9% (2.4,
13.2)
6.2% (4.3, 8.6) 4.4% (3.2, 5.8) 3.8% (2.1, 5.9)
% of total patient-related costs as a














% of total patient-related costs as a














aAverage patient costs for all participants combined is $7.33 (95% CI 3.70, 15.86) with transport and medication costs of $1.44 (95% CI 0.81, 2.18) and $2.25 (95%
CI 0.00, 7.55), respectively
bTotal integrated cost is the sum of total health service cost (Table 3) and total patient-related costs minus patient-paid medication costs to avoid duplication
cThe proportion of transport cost as a function of the monthly household income per health care visit for patients with single conditions was 3.3% (95% CI 2.1,
4.9) and 5.3% (95% CI 2.4, 10.7) for patients with multiple conditions. The overall proportion of transport costs as a function of monthly household income was
4.5% (95% CI 2.1, 9.6). Computed only for participants with a household income
dThe proportion of total out-of-pocket expenditure as a function of the monthly household income per health care visit for patients with single conditions was
10.3% (95% CI 7.9, 14.2) and 12.7% (95% CI 6.8, 24.0) for patients with multiple conditions. The overall proportion of patient-related costs as a function of monthly
household income was 11.7% (95% CI 7.3, 22.1). Computed only for participants with a household income
eThe overall proportion of total patient-related costs as a function of total integrated cost was 23.4% (95% CI 9.9, 54.3)
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that the costs for both conditions combined are still
lower than the costs of managing HIV infection. Our
HIV costs were like those derived in an earlier study
[29]. In the prevalence-based budget projection for the
year 2025, we considered demographic changes as well
disease-specific frailty in surviving all participant cat-
egories. It shows savings of 21.6% from the integrated
management of the three conditions included (see
annex). Given that far more people in Africa today die
from the complications associated with diabetes and
hypertension than with HIV infection, it is essential that
that integrated care for multi-morbidities within country
health systems is strengthened. Even then, transport and
other related costs will still be high and may even be
crippling for some households, as our study shows. New
innovative ways of managing chronic conditions are
needed, such as community care, inclusion of e-health
and less frequent appointments at health facilities, as is
the case for HIV infections.
In high-income countries, about 25% of adults have
multi-morbidity from chronic conditions [30, 31], while
the economic burden of multi-morbidity is largely un-
known. The exact burden is unknown in Africa, but
non-communicable conditions have risen sharply [32,
33] alongside a continuing high burden of HIV infection
and new models of chronic care management will be
needed in sub-Sahara Africa. Based on existing popula-
tion projections and the empirical health service costs
derived in this study, we estimate the economic health
service burden in people living with comorbidity (HIV
and/or diabetes and/or hypertension) will go up by
21.5% (range, 19.3%, 23.4%) on average, for the next 5
years, despite the included savings of 21.6% from the in-
tegration of services. By year 2030, the economic burden
may increase by 47.7% (range, 41.9%, 52.7%) compared
to the current economic burden in year 2020 (Fig. 2 and
Table A7 in the Additional file 1 and country statistics).
Even with the ongoing changing epidemiology, most
people in Africa will likely have a single chronic condi-
tion, at least for the decade to come and the costs asso-
ciated with this in a vertical clinical, compared with our
model, are unlikely to be appreciably different. The key
Table 5 Health worker and patient cost by disease condition based on measured time involvement (US$ 2020). Mean costs and
95% confidence intervals are given in parentheses





























































$1.05 (0.67, 1.37) $1.57 (1.17, 2.42) $1.59 (0.99, 2.63)
Table 6 Relative facility efficiency scores on the delivery of integrated care for people with HIV, diabetes and/or hypertension.
Values are given as means and ranges in parentheses











Doctors Nurses Other staff
Overall 3 (0–8) 4 (1–11) 6 (2–16) 0.82 (0.01–1.00) 0.39 (0.13–1.36) 0.61 (0.00–1.81) 0.86 (0.30–1.00)
HIV 3 (2–5) 3 (2–6) 4 (2–6) 1.00 (1.00–1.00) 0.30 (0.23–0.44) 0.91 (0.25–1.81) 0.89 (0.35–1.00)
NCD 1 (0–3) 2 (1–5) 6 (2–14) 0.68 (0.40–1.00) 0.48 (0.19–1.11) 0.30 (0.09–0.63) 1.00 (1.00–1.00)
OPD 5 (3–8) 7 (4–11) 9 (3–16) 0.60 (0.01–1.00) 0.47 (0.13–1.36) 0.33 (0.00–1.47) 0.68 (0.30–1.00)
NCD non-communicable disease, OPD outpatient department
Other staff: this includes laboratory personnel and pharmacists
aDrug availability — defined as the proportion of patients who get free drugs from the facilities before stock-outs occur
bStaff workload — the number of full-time staff divided by the number of daily patient visits
cNumber of laboratory tests per patient — the number of laboratory tests divided by the number of patients’ visits
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question will be which models of care lead to better clin-
ical and economic outcomes for patients with multiple
conditions.
This first economic cluster-based study on real-life in-
tegrated care has some study design limitations to con-
sider because it comprises a single-arm cohort over a 1-
year follow-up duration [15, 34]. In the explorative phase
of developing integrated care, we set-up this cohort
without a control arm to test its acceptability to patients.
Here, patients were given a choice to participate, as HIV
control in a new integrated setting could be weakened
due to stigma. This has guided the choice for a cohort
design that has demonstrated an increase in compliance
and control levels [12]. In our cohort study, a compari-
son group in a real-life setting (e.g., in a before-after
study or a control arm) would not present the correct
comparison in the absence of consistent drug supplies,
as in real-life shortages in diagnostics and medicines for
diabetes and hypertension control are common and pa-
tient adherence is therefore, likely, very limited. Sec-
ondly, while one may consider it unethical to withhold
proven-effective treatment in control groups [35], our
next follow-up study — already started — is a cluster-
randomised trial based, therefore, on equipoise effects
and harm of integration, pursuing a more rigorous and
larger design that is needed to assess the effects of inte-
gration [15, 36].
We want to argue that real-life economic costing stud-
ies are less subject to Hawthorne effects among pro-
viders or patient participants and that the clusters are
less prone to contamination: the benefits are less tan-
gible, and hence, the estimates are less biassed. We did
compare large groups of participants with a single condi-
tion to large within-cohort groups of participants with
multiple conditions in both countries and consider the
approach, in principle, rather robust, given the study de-
sign. Also, the follow-up period is long enough to arrive
stable economic estimates of clinical resource use as pa-
tients are already diagnosed and the treatment of pa-
tients with chronic conditions tend to stabilise within six
months, especially those with multiple conditions [12].
In principle, we expect some generalizable mecha-
nisms across similar settings as the potential service ef-
fects (less programme costs per patient and less health
worker cost) and effects for patients (reduction of visits)
are both rather intuitive, certainly for people with mul-
tiple conditions. This will need to be proven in a larger
multi-country cluster-trial, considering the existing situ-
ation and the implementation costs of the upscaled ef-
forts. In future research, one must distinguish carefully
studies addressing multi-morbidities and those address-
ing integration of care. The former would need individ-
ual randomisation while the latter needs cluster-
randomisation at a large scale.
However, presently, one cannot say much about coun-
try differences. We need more qualitative work [14] and
larger samples in the quantitative research, including
step-wedge designs.
There are many factors that will influence how inte-
grated services are implemented or the potential impact
Fig. 2 The effect of ageing and decreased survival on the total health service costs of managing people living with multiple conditions (HIV and/
or diabetes and/or hypertension) in Uganda and Tanzania in years 2020, 2025 and 2030, compared to baseline
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that the adoption of integration will have. As this was a
feasibility study, the findings are indicative of impact,
but more robust evidence is required before definitive
recommendations can be made. Impact will be influ-
enced by the prevalence of the individual conditions, or-
ganisation of health services including availability of
insurance and policy directions in each country. Based
on experience since the end of MOCCA, it seems that
integration might be better suited to smaller health facil-
ities with more limited resources. Larger health facilities
that are delivering more specialised care or who are
accepting referrals may be better suited to only imple-
menting some aspects of integration. In Uganda, the
smaller health facilities in the study have since fully inte-
grated their services after the end of MOCCA. This has
increased the provision of services, i.e., where there were
two HIV clinics per week, this is now available every
day. This is explored further in the MOCCA extension
study. In general, in other settings, one can expect
between-facility differences at baseline. Integration
would probably be less impactful in small facilities where
patients with different conditions are already managed
through the same channels, providing one other clear
mechanism towards integrated care. Ultimately, policy
decisions about integrated clinics need to combine gen-
eral principles with local factors.
Conclusion
In sum, this study is a first valid exploratory approach to
detail the economic costs and economies-of-scale of in-
tegrating services for chronic conditions in integrated
one-stop clinics in sub-Sahara Africa. It provides much
needed evidence on the probable efficiency of such
models of service provision for HIV, diabetes and hyper-
tension. Larger studies comparing directly, possibly
through multiple arms directly integrated primary care
with more vertical care models in a facility-randomised
way will be useful to assess the overall marginal conse-
quences, in terms of service and household impact of in-
tegrated care. The first results are certainly very
promising.
In this cohort study, we have demonstrated that one-
stop treatment of comorbidities is likely worthwhile and
an efficient strategy enhancing financial equity in service
provision for people with multiple conditions in sub-
Saharan Africa settings.
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